CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical ...

CytoMed (NASDAQ: GDTC) stock is down 33% over the last 24 hours. GDTC stock fell in a mixture of real trading time, the aftermarket and now this morning. The reason for the decline is simply that it ...

CytoMed (NASDAQ: GDTC) stock is up 100%. The rise in GDTC stock seems to be coming from the award of a patent. This is a very silly idea, quite ridiculous. Of course, it's just great for those who ...

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia ...

On Monday, CytoMed Therapeutics (NASDAQ:GDTC) stock is down 6.35% at $3.23 at last check Monday. The Singapore-based clinical-stage biopharmaceutical entered into a five-year Business & Research ...

As major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

GDTC is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of GDTC shares has increased $0.01 since the market last closed. This is a 0.76% ...